TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Cancer Categories

Breast

Karmanos Trial ID

MA-39

NCT ID

NCT03488693

Age Group

Adult

Scope

National

Phase

Phase III

Principal Investigator

Brian
Yeh, M.D., Ph.D.
Oncology - Radiation View Profile

Objective:

Primary Objective:

To compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not, defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.

Secondary Objectives:

To compare the invasive disease-free survival (DFS) between patients that received regional RT or not.
To compare the breast cancer mortality between patients that received regional RT or not.
To compare the overall survival (OS) between patients that received regional RT or not.
To compare the locoregional recurrence-free interval (LRRFI) between patients that received regional RT or not.
To compare the distant recurrence-free interval (DRFI) between patients that received regional RT or not.
To compare the toxicity between patients that received regional RT or not.
To compare arm volume and mobility measurements between patients that received regional RT or not.
To compare patient reported outcomes (PROs) and the quality of life (QOL) between patients that received regional RT or not.
To compare the cost effectiveness between patients that received regional RT or not.

Request an Appointment

Refer a Patient

NCI Dictionary of Cancer Terms

KCI Clinical Trials App

Eligibility

Inclusion Criteria:

Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care.
Patients must have been treated by BCS or mastectomy with clear margins of excision. Post-mastectomy positive margins for invasive disease and/or DCIS is not allowed. Multifocal disease (i.e. the presence of two or more foci or breast cancer within the same breast quadrant) and multicentric disease (i.e. the presence of two or more foci of breast cancer in different quadrants of the same breast) are allowed.
Patients with T3N0 disease are eligible.
Patients with disease limited to nodal micrometastases are eligible
Patients with nodal macrometastases (>2mm) treated by axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm).
Patients treated by mastectomy and SLNB alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm).
Patients must be ER ≥ 1% and HER2 negative on local testing
Patients must have an Oncotype DX recurrence score ≤25 obtained from testing of breast tumour tissue from a core biopsy or from the surgical specimen.
Patient must consent to provision of, and investigator(s) must agree to submit to the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative marker assays described in the protocol may be conducted
Patient must consent to provision of samples of blood in order that the specific correlative marker assays described in the protocol may be conducted.
Patients must have had endocrine therapy initiated or planned for ≥ 5 years. Premenopausal women will receive ovarian ablation plus aromatase inhibitor therapy or tamoxifen if adjuvant chemotherapy was not administered. For all patients, endocrine therapy can be given concurrently or following RT.
Patients may or may not have had adjuvant chemotherapy.
RT must commence within 16 weeks of definitive surgery if the patient is not treated with chemotherapy. If adjuvant chemotherapy is given, RT must begin within 12 weeks after the last dose. (Note: adjuvant chemotherapy may be ongoing at the time of randomization). Definitive surgery is defined as the last breast cancer-related surgery.
Patient's ECOG performance status must be 0, 1 or 2.
Patient's age must be ≥ 35 years.
For the first 736 eligible English or French-speaking subjects who have agreed to optional questionnaire completion: Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life, health utilities and lost productivity questionnaires in either English or French (note: enrollment completed 2022Aug02)
Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements
Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
In accordance with CCTG policy, protocol treatment is to begin within 6 weeks of patient randomization.
Women of childbearing potential must have agreed to use an effective contraceptive method. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months.

Exclusion Criteria:

Patients with nodal disease limited to isolated tumour cells (pN0i+ < 0.2 mm).
Patients with pT3N1 and pT4 disease (Note: patients with T3N0 are eligible).
Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy. (Patients with synchronous or previous ipsilateral LCIS are eligible.)
Synchronous or previous contralateral invasive breast cancer. (Patients with contralateral DCIS are eligible unless previously treated with radiation.)
History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years.
Patients who are pregnant.
Patients that have had prior ipsilateral chestwall/thoracic radiation.
Patients treated with chemo or endocrine therapy administered in the neoadjuvant setting for breast cancer. Endocrine therapy exposure 12 weeks or less prior to surgery is permitted.
Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT.

Locations

Karmanos Cancer Institute at McLaren Bay Region

3140 W Campus Dr.
Bay City, MI 48706
Get Directions

Phone: 989-667-2370

Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center

1221 South Drive
Mount Pleasant, MI 48858
Get Directions

Phone: 989-772-6811

Karmanos Cancer Institute at McLaren Clarkston

5680 Bow Pointe Dr
Clarkston, MI 48346
Get Directions

Phone: 248-922-6650

Karmanos Cancer Institute at McLaren Flint

4100 Beecher Rd
Flint, MI 48532
Get Directions

Phone: 810-342-3800

Karmanos Cancer Institute at McLaren Greater Lansing - Medical Oncology and Hematology

3520 Forest Rd.
Lansing, MI 48910
Get Directions

Phone: 517-975-9500

Karmanos Cancer Institute at McLaren Macomb

1080 Harrington Blvd
Mount Clemens, MI 48043
Get Directions

Phone: 586-493-7510

Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey

560 W Mitchell St
Petoskey, MI 49770
Get Directions

Phone: 231-487-3390

Karmanos Cancer Institute at McLaren Port Huron

1221 Pine Grove Ave
Port Huron, MI 48060
Get Directions

Phone: 810-982-5200

Applicable Disease Site

Therapies, Drugs, Devices